Applying the Growth Failure in CKD Consensus Conference: evaluation and treatment algorithm in children with chronic kidney disease.
Growth failure is a common and significant clinical problem for children with chronic kidney disease (CKD), particularly those with chronic renal insufficiency (CRI). Children with CRI (typically defined by a glomerular filtration rate [GFR] <75 mL/min/1.73 m2) who have growth impairment exhibit a variety of medical and psychological problems in addition to increased mortality. Growth failure in children with CKD is usually multifactorial in etiology, including abnormalities in the growth hormone (GH)-insulin-like growth factor (IGF)-I axis and a variety of nutritional and metabolic concerns characteristic of CKD. Proper management of these factors contributes to better growth in affected children. Although the safety and efficacy of recombinant human GH (rhGH) therapy in promoting growth in children with CKD are well established, recent data indicate that the use of rhGH administration in children with CKD and growth failure remains low. Recently, guidelines were developed by the Consensus Conference for Evaluation and Treatment of Growth Failure in Children with CKD. This paper focuses on the application of these guidelines to children with CKD.
Mahan
John D
JD
Department of Pediatrics, Division of Pediatric Nephrology, The Ohio State University College of Medicine, Columbus, OH, USA. MahanJ@pediatrics.ohio-state.edu
D000465:Algorithms; D002648:Child; D000013:Congenital Abnormalities / Q000209:etiology; D003245:Consensus Statements as Topic; D013006:Growth Hormone / Q000172:deficiency / Q000627:therapeutic use; D048788:Growth and Development; D019983:Guideline Adherence; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000172:deficiency; D008954:Models, Biological; D011908:Rationalization; D051436:Renal Insufficiency, Chronic / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy*
D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone